ARTHUR A. LEVIN - 15 Mar 2023 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
15 Mar 2023
Net transactions value
-$2,077
Form type
4
Filing time
17 Mar 2023, 16:36:51 UTC
Previous filing
15 Feb 2023
Next filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $124 +100 +0.52% $1.24* 19,430 15 Mar 2023 Direct F1
transaction RNA Common Stock Sale $2,201 -100 -0.51% $22.01 19,330 15 Mar 2023 Direct F1
holding RNA Common Stock 273,872 15 Mar 2023 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -100 -0.15% $0.000000 68,323 15 Mar 2023 Common Stock 100 $1.24 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.